JP2016500682A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500682A5
JP2016500682A5 JP2015537240A JP2015537240A JP2016500682A5 JP 2016500682 A5 JP2016500682 A5 JP 2016500682A5 JP 2015537240 A JP2015537240 A JP 2015537240A JP 2015537240 A JP2015537240 A JP 2015537240A JP 2016500682 A5 JP2016500682 A5 JP 2016500682A5
Authority
JP
Japan
Prior art keywords
amino acid
pharmaceutical composition
composition according
glp
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015537240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/071618 external-priority patent/WO2014060472A1/en
Publication of JP2016500682A publication Critical patent/JP2016500682A/ja
Publication of JP2016500682A5 publication Critical patent/JP2016500682A5/ja
Withdrawn legal-status Critical Current

Links

JP2015537240A 2012-10-17 2013-10-16 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸 Withdrawn JP2016500682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12188872.1 2012-10-17
EP12188872 2012-10-17
US201261715416P 2012-10-18 2012-10-18
US61/715,416 2012-10-18
PCT/EP2013/071618 WO2014060472A1 (en) 2012-10-17 2013-10-16 Fatty acid acylated amino acids for oral peptide delivery

Publications (2)

Publication Number Publication Date
JP2016500682A JP2016500682A (ja) 2016-01-14
JP2016500682A5 true JP2016500682A5 (enExample) 2016-12-08

Family

ID=47049065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015537240A Withdrawn JP2016500682A (ja) 2012-10-17 2013-10-16 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸

Country Status (5)

Country Link
US (1) US20150273069A1 (enExample)
EP (1) EP2908844A1 (enExample)
JP (1) JP2016500682A (enExample)
CN (1) CN104717972A (enExample)
WO (1) WO2014060472A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162195A1 (en) * 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
ES2929218T3 (es) 2015-01-12 2022-11-28 Enteris Biopharma Inc Formas farmacéuticas orales sólidas
WO2016120380A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CA3021660A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
HRP20240485T1 (hr) * 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN120617159A (zh) * 2018-10-26 2025-09-12 诺和诺德股份有限公司 稳定的司美鲁肽组合物及其用途
EP3883595A4 (en) 2018-11-19 2022-12-14 Receptor Holdings, Inc. N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID-BASED COMPOSITIONS
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
US20240041983A1 (en) * 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022152131A1 (zh) * 2021-01-12 2022-07-21 广州新济药业科技有限公司 司美格鲁肽可溶性微针贴片及其制备方法
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
JP2025508982A (ja) * 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
CN116848243B (zh) 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
CA2549582A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2006003781A1 (ja) 2004-06-30 2006-01-12 Pioneer Corporation バックアップ装置および車載機器
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー/エス A−b−c−d−で誘導体化されたペプチドとその治療用途
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
WO2012140155A1 (en) * 2011-04-14 2012-10-18 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery

Similar Documents

Publication Publication Date Title
JP2016500682A5 (enExample)
JP2013518115A5 (enExample)
AR094178A1 (es) Derivados de exendina-4 funcionalizada
ES2528599T3 (es) Análogos truncados de un polipéptido insulinotrópico dependiente de glucosa
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
JP2014512366A5 (enExample)
EA201170337A1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения
WO2014142102A1 (ja) 液体水性組成物
JP2013155195A5 (enExample)
RU2012101274A (ru) Соединения глюкагона, активные в отношении рецептора gip
PE20241305A1 (es) Analogos de amilina
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
RU2020120797A (ru) Пептидные композиции
MY163100A (en) Short antimicrobial lipopeptides
JP6580581B2 (ja) 注射用医薬組成物
CA2776302A1 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
JP2009533355A5 (enExample)
WO2020230780A1 (ja) Ras阻害ペプチド
JP2015533369A5 (enExample)
CN116888146A (zh) 胰高血糖素样肽-1受体拮抗剂
JP6953579B2 (ja) 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用